Last updated: July 27, 2026
Executive summary
- Dayvigo (lemborexant, Eisai) is an oral dual orexin receptor antagonist (DORA) positioned for insomnia treatment with differentiated efficacy and tolerability versus earlier sleep agents.
- The near-to-mid term market outlook is shaped by: (1) label breadth and prescribing adoption, (2) competitive intensity from other DORAs and “Z-drugs”/benzodiazepine receptor agonists, (3) payer controls and prior authorization, (4) life-cycle differentiation through additional indications, formulations, and real-world evidence.
- Without a specific, dated clinical-trials dataset and FDA/Orange Book snapshots provided in the prompt, a complete, accurate trial-by-trial update and patent-state-based exclusivity timeline cannot be produced.
What is the latest clinical trials update for Dayvigo (lemborexant)?
Key point: A valid “clinical trials update” requires an up-to-date registry and publication crosswalk (ClinicalTrials.gov, EU CTR, peer-reviewed results) with current statuses and dates. The prompt does not provide a dated source list or trial identifiers.
Which Dayvigo studies are most relevant to market expansion?
Common high-impact study categories for insomnia products include:
- Phase 3 efficacy and safety in subpopulations (elderly, comorbidities, chronic insomnia phenotypes)
- Long-term extension studies (maintenance of efficacy, sustainability of effect)
- Comparative trials versus other insomnia classes (Z-drugs, DORAs, melatonin agonists)
- Real-world outcomes studies (adherence, discontinuation, work productivity, falls)
- Special populations (hepatic/renal impairment, drug-drug interaction cohorts)
How do results map to label and prescribing behavior?
For insomnia, incremental differentiation usually depends on:
- Time-to-persistent effect and durability across nights
- Next-day impairment and discontinuation rates
- Effects on both sleep onset and sleep maintenance (where studied)
- Safety signals that influence prescriber risk tolerance (falls, complex sleep behaviors)
How large is the insomnia market for Dayvigo (lemborexant), and what segments drive growth?
Key point: Revenue projections require market sizing inputs (US vs EU vs Japan, diagnosed prevalence, treatment penetration, class mix). The prompt does not include market figures, geography targets, or pricing assumptions.
Segmentation that typically drives DORA share
- Chronic insomnia vs short-term insomnia lines
- Elderly and frail patients
- Patients previously exposed to benzodiazepine receptor agonists (BRAs) or Z-drugs
- Payers that steer toward non-controlled alternatives
- Comorbidity-driven prescribing (e.g., patients where safety profile matters most)
What is the competitive landscape for Dayvigo versus other insomnia drugs?
Key point: Competitive share depends on head-to-head or indirectly comparable efficacy endpoints, formulary placement, and dosing convenience. A complete competitive analysis needs named comparators and formulary status by geography and plan type.
Key competitor classes (insomnia)
- Other DORAs (orexin receptor antagonists)
- Z-drugs and related BRAs
- Ramelteon and other melatonin-pathway agents
- Sedating antidepressants used off-label in insomnia
How competition changes the adoption curve for Dayvigo
- If formulary access is restricted, DORA share growth usually slows
- If payers prefer one DORA as a “preferred brand,” switching costs drop for patients moving between DORAs
- If generic BRAs/Z-drugs dominate lower tier pricing, incremental demand for DORAs can depend on safety-focused prescriber segments
What is the revenue projection for Dayvigo (lemborexant) from 2024 to 2035?
Key point: A credible projection needs baseline revenue, geography mix, net price assumptions, and explicit market share trajectories. The prompt contains none of these.
Model structure used for revenue projection (what the projection must quantify)
A standard projection framework ties:
- Addressable population growth (diagnosed/treated prevalence)
- Treatment penetration shift from older classes to DORAs
- Net price evolution (rebates, payer contracts, reference pricing)
- Share by insomnia segment (chronic vs acute/short-term)
- Persistence and discontinuation (real-world adherence)
- Brand erosion from generics in background classes
What risks dominate upside/downside
- Rapid payer-driven substitution to another DORA
- Label-constrained growth if the indication scope is limited
- Greater-than-expected brand erosion in high-usage channels
- Safety concerns affecting formulary decisions
When does Dayvigo lose exclusivity, and what patents protect lemborexant?
Key point: Exclusivity and patent protection require a verified Orange Book entry (US) plus global patent family data with grant/expiration and any pediatric exclusivity or patent term adjustments. No patent or regulatory dataset is supplied.
US regulatory exclusivity items that typically matter
- 505(b)(1) or 505(j) relevant exclusivity
- Orphan/novelty exclusivity (if applicable)
- Pediatric exclusivity add-ons (if triggered)
- Patent term and any patent-specific exclusivity
Patent estate components that typically block generics
- Drug substance patents
- Drug product/formulation patents (dosage form, release profile)
- Method-of-use patents (indication, dosing regimens)
- Manufacturing process patents (solid state, polymorphs, synthesis intermediates)
What is the Orange Book status of Dayvigo (lemborexant)?
Key point: Orange Book status must be read directly from FDA’s Orange Book with listing numbers and expiration dates. The prompt provides none.
What the Orange Book listing must show to support a launch-risk view
- Drug product IDs
- Patent numbers and listed expiration dates
- Orange Book exclusivity codes and end dates
- Any listed “use” vs “drug substance/product” patents
Do Paragraph IV filings pose generic entry risk for Dayvigo?
Key point: Paragraph IV risk requires a Paragraph IV notice data source (e.g., FDA 705(b)(2) reports) and linkage to Orange Book patents. The prompt provides none.
How to assess entry likelihood
- Number of Orange Book patents likely to be challenged
- Strength of independent claims in pivotal patents
- Likelihood of settlement or FDA approval design-around
How does Dayvigo compare with other DORAs on efficacy and safety?
Key point: Comparative conclusions require either head-to-head trials or standardized interpretation of endpoints (sleep onset latency, WASO, TST, subjective and objective measures) with consistent timing, population, and scale.
Endpoints that typically drive formulary decisions
- Sleep latency and sleep maintenance (WASO)
- Total sleep time (TST)
- Next-day impairment and adverse events
- Falls risk in elderly populations
- Complex sleep behaviors and related discontinuation
What Dayvigo formulations and dosing are protected by patents?
Key point: Formulation patent scope depends on specific patent claims, dosage strengths, and manufacturing methods. The prompt provides none.
Formulation areas that commonly generate protectable IP
- Specific dosing strengths and dosage unit compositions
- Excipient systems affecting dissolution and stability
- Controlled-release alternatives (if developed)
- Polymorph or solid-state form patents (if disclosed)
What patent litigation affects Dayvigo (lemborexant)?
Key point: Litigation requires dockets and case identifiers, including parties, asserted patents, and outcomes. None are provided.
What to extract from litigation for business decisions
- Venue and judge, timeline, and stay/expedite posture
- Claim construction rulings
- Settlement terms (licensed entry date, carve-outs)
- Injunction status and ITC-related threats
Key takeaways
- A complete clinical trials update and a data-backed revenue projection for Dayvigo require a dated clinical/regulatory dataset (trial registry snapshot and FDA/Orange Book snapshot) plus baseline commercial metrics.
- Competitive and exclusivity-driven outcomes are the primary determinants of medium-term growth for DORAs in insomnia.
- Patent and Orange Book status are the gating inputs for generic entry risk analysis, including Paragraph IV and settlement/launch timing.
FAQs
- What insomnia clinical endpoints matter most for DORA (orexin antagonist) adoption?
- How do payer restrictions (prior authorization, step therapy) typically affect DORA market share?
- What types of patents most often determine generic entry timing for insomnia drugs?
- Which real-world metrics best predict persistence for insomnia therapies like Dayvigo?
- How do safety signals (falls, next-day impairment) influence formulary placement for insomnia brands?
References
- FDA Orange Book (Drug Products, Inspections, and Regulatory Information) database.
- ClinicalTrials.gov database.
